RO4491533
From Wikipedia, the free encyclopedia
 |
This article relies too much on references to primary sources. (April 2012) (Learn how and when to remove this template message) |
 |
|
| Clinical data | |
|---|---|
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 579482-31-8 |
| PubChem (CID) | 11158623 |
| IUPHAR/BPS | 6226 |
| Chemical and physical data | |
| Formula | C24H20F3N3O |
| Molar mass | 423.430 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
RO-4491533 is a drug developed by Hoffmann-La Roche which acts as a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors (mGluR2/3), being equipotent at mGluR2 and mGluR3 but without activity at other mGluR subtypes. In animal studies, RO-4491533 produced antidepressant effects and reversed the effects of the mGluR2/3 agonist LY-379,268 with similar efficacy but slightly lower potency than the mGluR2/3 antagonist LY-341,495.[1] A number of related compounds are known, with similar effects in vitro and a fairly well characterized structure-activity relationship.[2]
See also[edit]
References[edit]
- ^ Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I, Schneider M, Legrand C, Parron D, Girard F, Bessif A, Poli S, Vaugeois JM, Le Poul E, Celanire S. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. Journal of Neurogenetics. 2011 Dec;25(4):152-66. PMID 22091727
- ^ Hemstapat K, Da Costa H, Nong Y, Brady AE, Luo Q, Niswender CM, Tamagnan GD, Conn PJ. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 2007 Jul;322(1):254-64. PMID 17416742
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
